With the approval of Cobenfy as the first new schizophrenia drug of its kind, a resurgence of hope, commercial opportunity, and a regulatory path forward for new mechanisms beyond D2 agonism has reinvigorated the psychosis treatment landscape. At the same time, the inherent challenges of developing therapies for psychosis, underscored by setbacks of new candidates like Emraclidine, highlight the need for industry to unite, share experiences and learn from each other. 

• Decipher the underlying mechanisms of psychosis to uncover transformative new targets 

• Discover more translatable tools for predicting the antipsychotic efficacy of new drugs 

• Navigate biological and clinical heterogeneity of psychosis to innovate more targeted treatment approaches 

• Streamline the regulatory path for new psychosis treatments with new mechanisms and new labels 

Discover Cutting-Edge Technologies: Explore the latest innovations designed to drive advancements in discovery, translational and clinical development.  

Connect with Industry Leaders: Engage directly with key stakeholders to explore solutions that address your R&D challenges and accelerate progress in your field. 

Maximize Networking Opportunities: Take advantage of structured networking sessions to form new and meaningful connections with other industry players.